Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought we could agree on the clear sky feeling coming sooner than later. In regards to financing, as has been described elsewhere, the value is like a numerator denominator. If you only present one side you can say dilution, but to be fair, the balancing force is continued stellar results phase I, then even more positive force coming from phase II start. Lets not confuse a start up biotech with the expectations of a large cap. stock, two different worlds.
I think it is fair to say that some of us are weary travelers since the road has been a long one, it is longer when certain milestones have not passed, like a trip where you're not sure of the location or an important turn. I know that feeling. But I also know the feeling of finally seeing that turn, and the relief of finally arriving. For us, I feel we will feel that relief. We await a response from an agency. Best to focus on other things that bring you joy in the mean time. Some may paint a dark picture, all I can say is, it may be darkest before the dawn. There will be light for many. Actc, stay the course.
Yes. It would put me in a new tax category, and a new house, etc.
There is some confusion over whether phase I trial is on hold, and the info yesterday that a few injections are left to take place. IMO, I think the recruitment of patients is complete so there is no more recruitment for phase I.
It would be interesting to know how much IP is collateral...
July 2nd 2013. google: Celegene Tengion
from fiercebiotech.com:
Celgene has invested further in the cash-hungry regenerative medicine specialist Tengion, which tapped the biopharma powerhouse ($CELG) and other backers for a total of $33.6 million to support its two lead programs in early clinical development.
The bulk of the latest financing comes from the sale of $18.6 million in convertible notes to repeat investors Bay City Capital, Deerfield Management, HealthCap and RA Capital Management as well as new investors QVT Financial and Perceptive Life Sciences.
Celgene, which has a cellular therapy unit, forked over $15 million in cash for the right to first negotiation on Tengion's Neo-Kidney Augment product candidate, which aims to restore renal function to delay transplantation or dialysis for patients with chronic kidney disease. Based on a previous deal, Celgene has similar rights to Tengion's experimental Neo-Urinary Conduit system for cancer patients who seek implants after having their bladders surgically removed.
Celgene also formed a new collaboration with Tengion that gives the Summit, NJ-based drugmaker an exclusive option to acquire assets such as its technology for growing esophageal implants. In an October 2012 financing, Tengion raised $5 million from Celgene, which has rights to the biotech outfit's two leading product candidates and has helped keep its operations afloat.
I wish the NIH would follow through with their proposed redefinition of the embryonic stem cell.
http://seekingalpha.com/article/1805832-tengion-a-cautionary-tale-for-regenerative-medicine-bulls
Of course they don't mention the financing arrangement with Celegene because with some coverage its all black and white from Alpha. I'm not impressed with Alpha for this reason.
Seeking Alpha published a summary of why Tengion is pretty low. They didn't seem to mention the financing from the Pharma deal. Any one else out there have tengion and consider filing a law suit against Tengion for the deception listed in the Alpha article?
I think they are attempting to skip the last cohort and go to the next phase or skip the next phase and go to phase III.....
I have seen that one of the litigants (from the group of them associated with this action) has a default judgement filed. It's been noted though, that this has nothing to do with the status of ACTC's case. I hope there is info out there to support the conclusion of the case, I'd like to see that as well.
Her results indicate a halting of the disease progression. That also happens to be the goal of the trial. This is what I recall.
Where is the pulse on this one?
From some time back shareholders were clamoring for a polished video to help promote the company. It's nice to see it come out. I do not understand why any shareholders would complain...
Here is what 20/400 vision looks like insert-text-here
This is really a great idea, putting the video out on youtube, it is one of the things shareholders have been wanting for a while now. There are other videos on youtube about advanced Cell Technology, but this is a polished 3 minute commercial. I suggest you all who support ACTC share the link on your social media!
http://www.advancedcell.com/documents/0000/0474/act-annual-shareholders'-meeting-10.22.13.pdf
ok, didn't they mention there would be a film link posted on their website. Let me know if and where the link is. Thanks
You can tell it's a real company by all the videos of their products on youtube, plus all the sales listed on their filings...huh?
ACTC is ready and awaiting...the train is on the tracks, picking up speed!
It is interesting to note that the share price went from around 7 cents to around 6 cents around mid day of the ASM. It is interesting because any important news that would drive the pps is PR'd. The sophisticated trader would have sold earlier, so the timing indicates?????
I'll be interested in this when it reports revenue, and pps gets back to above ten cents per share.
Interesting Osiris made a deal with Mesoblast for its ceMSC ...Prochymal business, a deal that may reach 100 million $.
FDA animal trials last longer than human FDA trials....wait, that doesn't make sense, does it?
I just voted...For
So would you say Caldwell and Rabin knew exactly what each other was doing, to be sure, we don't know how knowledgeable they were of each others actions, just like people in any office don't know what they each are doing. I give the benefit of the doubt, until proven otherwise. ACTC is doing a great job now. More and more solid all the time. FDA approval, solid. Saftey results, solid. FDA approved IIa trial, solid.
Regarding Rabin you said
I think it's kind of weird that Google finance doesn't show ACTC stock price anymore. What's up with that?
Well I've read that book and I feel the reviewer has missed the irony of the title. Bob Knight acknowledges that he is about eliminating the negative aspects of the game to win, and by ignoring what is wrong, problems don't get solved. ACTC has some problems that they are solving, but the negativity we see on MB is presented often in a way which seems to indicate an agenda. That too is the negativity we are trying to eliminate, as would Bob Knight.
Good post!
Amazing, NIH awards Neostem for Vcel research, even though other researchers can't verify existence of Vcel....
You meant 4 month, not 4 year, correct?
Some folks compute pps starting with the market cap. Not that long ago the Cap for ACTC hovered around 300 million dollars all the time. Lets say there are 2.5 billion shares out, the PPS ought to be at 12 cents a share, when 2.7 billion shares are out, it ought to be at 11.11 cents a share. If 3.7 billion shares were out, then the pps really should be at 8.1 cents per share. But that 300 million number was before trial approval and all the great results...when those are published the market cap. really should reflect somewhere at or north of 450 million market cap. With this cap number and assuming 2.7 billion shares would be out, the pps should be 16.6 cents.
I follow your logic, guy3.
Since the A/G recommendations are in, it seems somewhat likely a deal should be coming relatively soon.....hope.
So the document they refer to is a chart that only lists totals and no details. I guess A/G has to have better evidence than that, so the courts will allow them to have a short time to fix that.
Its interesting that in one of the claims (not the 4th) that Burrows, spouse of then CEO Caldwell, is a plaintiff. ACTC's defense as I read the publication, is that the agreement on warrants started before the pricing period, and an extension was granted but a lockout period was in place till after the pricing period was over. This will be allowed to be argued.
I guess the A/G thing will continue till ?????
Recommendation is 4th claim denied, without prejudice. The fourth claim is the one with reference to the SEC case.
"ACT argues that the evidence which Aronson and Gorton submitted in connection
with their opposition to the motion for sanctions provides no support for a claim because
it “does not show that ACT sold stock for less than $2.20 per share during the Pricing
Period.” (Def. Reply re Sanctions (Docket No. 86) at 10). This does not appear to be
correct since when the total amounts paid for the stock listed on the chart are divided by
the number of shares purchased, they yield at least some per share prices below $2.20 per
share."
JMO but it seems that "at least some" were below $2.20 per share seems to imply not many?
When the published data rolls out, its going to make a lot of grumpy investors happy. I hope you are an investor, not just a parasitic trader looking for easy quick cash.